Erudio Healtherudio.com
Sponsor
Nantes University Hospital trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by Nantes University Hospital: IFM 2022-01. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 2 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Nantes University Hospital). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| IFM 2022-01 NCT06353022 · Nantes University Hospital | newly diagnosed multiple myeloma | Phase 2 | 17 | 4 | Focused | Nov 1, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| IFM 2018-04 NCT03606577 · Nantes University Hospital DeepView → | high-risk newly diagnosed multiple myeloma | Phase 2 | Deep | View | |||
| OAsIs NCT02558816 · Nantes University Hospital FocusedView → | relapsed/refractory mantle cell lymphoma | Phase 1/Phase 2 | Focused | View | |||